PTO/SB/08a (05-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10587804	
INFORMATION DIOOLOGUEE	Filing Date		2007-06-07	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Bouqu		uin, T.	
	Art Unit			
	Examiner Name			
	Attorney Docket Numb	er	0279us310	

									_		
U.S.PATENTS									Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	of cited Document			Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1										
If you wis	h to ac	dd additional U.S. Paten	it citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20030124555	A1	2003-07	-03	Brasch, et al.					
	2	20040106118	A1	2004-06	-03	Kolmar, et al.					
	3	20020086427	A1	2002-07	-04	Leiden, et al.					
If you wis	h to ac	dd additional U.S. Publis	shed Ap	plication	citation	n information p	please click the Add	button	. Add		
				FOREIC	N PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²			Publication Date	Name of Patentee Applicant of cited Document	/ 1	where Rel	or Relevant	T5
	1	1162270	EP		A2	2001-12-12	SCRIPPS RESEAR INST	СН			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10587804
Filing Date		2007-06-07
First Named Inventor Bouqu		uin, T.
Art Unit		
Examiner Name		
Attorney Docket Number		0279us310

	2	1477808	EP	A1	2004-11-17	PROBIOGEN AG		
	3	2002034906	wo	A2	2002-05-02	GEORG AUGUST UNI GOETTINGEN		
	4	2003014361	WO	A1	2003-02-20	ALTANA PHARMA AG		
	5	2003099996	WO	A2	2003-12-04	Biogen, Inc.		
	6	2001044516	WO	A2	2001-06-21	Tularik Inc.		
If you wis	h to ac	d additional Foreign Pa	atent Document	citation	information pl	ease click the Add buttor	1 Add	
			NON-PATEN	1T LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	xaminer Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T 5
	1	Abo T., et al. SsrA-mediated protein tagging in the presence of miscoding drugs and its physiological role in Escherichia coli. Genes Cells 7(7):629-638, 2002.						
	2	Arner E.S.J., et al. High-level expression in Escherichia coli of selenocysteine-containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA, selB and selC genes. J. Mol. Biol. 292(5):1003-1016, 1999.						
	3	Bedwell D.M., et al Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nature Med. 3:1280-1284, 1997.						
	4	Barton-Davis E.R., et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest. 104:375-381, 1999.						

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10587804
Filing Date		2007-06-07
First Named Inventor Bouqu		uin, T.
Art Unit		
Examiner Name		
Attorney Docket Number		0279us310

5	Burke J.F and Mogg, A.E. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res. 13 (17):6265-6272, 1985.	
6	Chang C.C., et al. Evolution of a cytokine using DNA family shuffling. Nat. Biotechnol. 17(8):793-797, 1999.	
7	Gorman C.M., et al. Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 11 (21):7631-7648, 1983.	
8	Howard M., et al. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Medicine 2:467-469, 1996.	
9	Hunt L., et al. Fluorescent proteins in animal cells for process development:optimization of sodium butyrate treatment as an example. Biotechnol. Bioeng. 77(5):528-537, 2002.	
10	Ikezawa, H. Glycosylphosphatidylinositol (GPI)-anchored proteins. Biol. Pharm. Bull. 25 (4):409-417, 2002.	
11	Kawagishi J., et al. Structure, organization, and transcription units of the human alpha-platelet-derived growth factor receptor gene, PDGFRA. Genomics 30 (2):224-232, 1995.	
12	Kozak, M At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J. Mol. Biol. 196(4):947-950, 1987.	
13	Kurtzman A., et al. Advances in directed protein evolution by recursive genetic recombination:applications to therapeutic proteins. Curr. Opin. Biotechnol. 12(4):361-370, 2001.	
14	Manuvakhova M., et al. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6(7):1044-1055, 2000.	
15	Millan, J.L. Molecular cloning and sequence analysis of human placental alkaline phosphatase. J. Biol. Chem. 261 (7):3112-3115, 1986.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10587804
Filing Date		2007-06-07
First Named Inventor Bouqu		uin, T.
Art Unit		
Examiner Name		
Attorney Docket Number		0279us310

	16	Pack P., et al. Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J. Mol. Biol. 246:28-34, 1995.							
	17	Pack P., et al. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Biotechnol. 11:1271-1277, 1993.							
	18		Pack P., and Plueckthun, A. Miniantibodies:use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry 31:1579-1584, 1992						
	19		er E., et al. Phenotypic suppression of nonsense mutants in yeast by aminoglycoside an 2):148-150, 1979.	tibiotics. Nature 277					
	20		Stansfield I., et al. The products of the SUP45 (eRF1) and SUP35 genes interact to mediate translation termination in Saccharomyces cerevisiae. EMBO J. 14:4365-4373, 1995.						
	21	Whal	Whalen R., et al. DNA shuffling and vaccines. Curr. Opin. Mol. Ther. 3 (1):31-36, 2001.						
	22	Yamauchi T., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (6941):762-769, 2003.							
	23	Zhouravleva G., et al. Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO J. 14(16):4065-4072, 1995.							
If you wis	h to a	dd add	ditional non-patent literature document citation information please click the Add b	outton Add					
	<u> </u>		EXAMINER SIGNATURE						
Examiner Signature Date Considered									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									
¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.									